issues

November/December 2017

COVER

R&D PARTNERSHIPS – Partnering for Progress: How Collaborations Are Fueling Biomedical Advances

Neil Lesser and Matt Hefner analyze biopharmaceutical partnerships created throughout the past several decades, and based upon a comprehensive database of partnerships formed between 1980 and 2014, they found that R&D-focused partnerships have grown substantially.

FEATURES

NEXT-GENERATION SEQUENCING – Emerging Clinical Applications & Projections to 2022

Laurie L. Sullivan and John Bergin, MS, MBA, say the growth curve for clinical applications of NGS is approaching an upward trajectory as existing applications gain traction and new ones begin to establish a foothold.

CANCER IMMUNOTHERAPY – Building on Initial Successes to Improve Clinical Outcomes

Allan B. Haberman, PhD, provides an updated discussion of approved and clinical-stage agents in immuno-oncology, including recently approved agents. He also addresses how researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients.

ONCOLOGY DIAGNOSTICS – Advancements Paving the Way for More Tailored Drugs

Divyaa Ravishankar, MS, says pharmaceutical companies have been subjected to a wide variety of external forces compelling them to get innovative about development of new platforms, liaise with new partners, leverage big data toward precision and predictive diagnosis, and identify new markers.

CENTRALIZED BIOMETRICS – The Backbone of a Global Clinical Data Strategy

Paul Fardy details the steps needed to implement a successful global clinical data strategy and how to approach developing a centralized process that results in transparency, traceability, accuracy, and collaboration.

EXECUTIVE INTERVIEW – Lonza Pharma & Biotech: Taking on the Next Challenges in Small Molecules

Gordon Bates, Head of Chemical Division at Lonza Pharma & Biotech, shares his perspective about industry needs and how strategic acquisitions are enhancing Lonza’s position as a development and manufacturing partner of choice.

R&D PARTNERSHIPS – Partnering for Progress: How Collaborations Are Fueling Biomedical Advances

Neil Lesser and Matt Hefner analyze biopharmaceutical partnerships created throughout the past several decades, and based upon a comprehensive database of partnerships formed between 1980 and 2014, they found that R&D-focused partnerships have grown substantially.